Valeritas Holdings Inc. has developed the V-Go Wearable Insulin Delivery Device (V-Go) for patients with Type 2 diabetes.

According to the company's Web site, V-Go is a disposable device indicated for "continuous subcutaneous infusion of insulin over 24 hours at preset rates and on-demand bolus dosing in two-unit increments in adult patients requiring insulin."

Part of the small, lightweight wearable is an injection-molded cartridge made of TOPAS cyclic olefin copolymer (COC) from TOPAS Advanced Polymers. “TOPAS COC fills an important role in the cartridge system of the V-Go insulin delivery device,” stated Geoffrey Jenkins, executive vice president of manufacturing and research and development for Valeritas, in a press release. “We find it to be highly stable in contact with the drug and it has great optical clarity; moreover, it offers good injection molding characteristics with excellent dimensional stability and minimal shrinkage.”

Glass-clear TOPAS resin features very low leachables and extractables compared with glass and other medical-grade polymers for drug delivery and thus preserves long-term drug purity and enables better quality at high yields, TOPAS stated in the release. COC also offers a non-ionic, minimally reactive surface.

Valeritas reports that users switching from multiple daily insulin shots to V-Go significantly lowered their glucose levels and reduced their insulin use by as much as 44% per day, it was reported in the release.

TOPAS will showcase this project at the upcoming MD&M West 2018 show in Anaheim Feb. 6-8  (Booth #666) and Pharmapack in Paris, Feb. 7-8 (Stand B23).